COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
DelveInsight’s “Wet Age-Related Macular Degeneration (Wet AMD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration (Wet AMD), historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration (Wet AMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Wet Age-Related Macular Degeneration (Wet AMD) market report provides current treatment practices, emerging drugs, Wet Age-Related Macular Degeneration (Wet AMD) market share of the individual therapies, current and forecasted Wet Age-Related Macular Degeneration (Wet AMD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration (Wet AMD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration (Wet AMD) market.
Some of the key facts of Wet Age Macular Degeneration
●Wet Age related macular degeneration was the third most common cause of moderate to severe visual impairment globally. The global prevalence of ARMD among those aged 45 to 85 years old was 8.7%, with a prevalence of 0.4% for advanced ARMD. Early ARMD is more common among those of European ancestry than in Asians, and ARMD of any stage is less common in those of African ancestry. The global prevalence of any stage of ARMD is predicted to increase from 196 million people in 2020 to 288 million by 2040.
●Approximately 10% of patients with ARMD develop the neovascular disease. In the absence of anti-VEGF therapy, between 79% to 90% of those eyes will eventually become legally blind due to complications from neovascularization.
Key Benefits of Wet Age-Related Macular Degeneration Market Report:
●The report covers the descriptive overview of Wet Age-Related Macular Degeneration (Wet AMD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
●Comprehensive insight has been provided into the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology and treatment in the 7MM
●Additionally, an all-inclusive account of both the current and emerging therapies for Wet Age-Related Macular Degeneration (Wet AMD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
●A detailed review of the Wet Age-Related Macular Degeneration (Wet AMD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
●The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Wet Age-Related Macular Degeneration (Wet AMD) market
Got queries? Click here to know more about the Wet Age-Related Macular Degeneration Market Landscape
Wet Age-Related Macular Degeneration Overview
Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It’s generally caused by abnormal blood vessels that leak fluid or blood into the macula (MAK-u-luh). The macula is in the part of the retina responsible for central vision.Wet macular degeneration is one of two types of age-related macular degeneration. The other type dry macular degeneration — is more common and less severe. The wet type always begins as the dry type.Early detection and treatment of wet macular degeneration may help reduce vision loss and, in some instances, recover vision.
Wet Age-Related Macular Degeneration Epidemiology Insights:
●Wet AMD prevalence varies greatly by ethnicity, with non-Hispanic White Europeans carrying most of the disease burden. We use the terms race and ethnicity in this review, as did the original study’s authors. Since participants are evaluated diversely in each research, we do not attempt to standardize the names. Notwithstanding a little fluctuation, there is still a significant chronic burden among Hispanics (10.4%), Africans (7.5%), and Asians (7.4%).
●In a population-based cohort study that combined data from three population-based cohort studies (mean age: 60.1-65.7 years), age-adjusted dry AMD incidence ranged from 0.3% to 0.4%, with follow-up times ranging from 4.8 to 6.5 years; increased incidence was linked to late-stage AMD disease at baseline. In a North American study (N = 3,549), the incidence of dry AMD was also associated with baseline drusen status, with the 10-year incidence risk of dry AMD diagnosis increasing from 9.9% in patients with large bilateral drusen at baseline (n = 241) to 44.3% in patients with large bilateral drusen and RPE changes at baseline (n = 636) and 53.9% in patients with late AMD (dry or wet) in one eye at baseline (n = 390).
Wet Age-Related Macular Degeneration Epidemiological Segmentation
●Wet Age-Related Macular Degeneration prevalent cases
●Wet Age-Related Macular Degeneration age-specific cases
●Wet Age-Related Macular Degeneration Diagnosis and treatable cases
●Wet Age-Related Macular Degeneration treatment cases
Wet Age-Related Macular Degeneration Market Outlook
The Wet Age-Related Macular Degeneration (Wet AMD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Wet Age-Related Macular Degeneration (Wet AMD) market trends by analyzing the impact of current Wet Age-Related Macular Degeneration (Wet AMD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Wet Age-Related Macular Degeneration (Wet AMD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Wet Age-Related Macular Degeneration (Wet AMD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Wet Age-Related Macular Degeneration (Wet AMD) market in 7MM is expected to witness a major change from 2019-2032.
Learn more by requesting for sample @ Wet Age-Related Macular Degeneration Market Landscape
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Wet Age-Related Macular Degeneration
4. Disease Background and Overview
5. Epidemiology and patient population
6. The United States
7. EU 5
8. Wet Age-Related Macular Degeneration Emerging Therapies
9. Wet Age-Related Macular Degeneration Cancer Market Outlook
10. Market Access and Reimbursement of Therapies
11. Appendix
12. Wet Age-Related Macular Degeneration Report Methodology
13.DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight
Click here to read more about Wet Age-Related Macular Degeneration Market Landscape
Trending Reports
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com